Kacy buys GILD 81.14: Gileadâs Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challen ...
Data Presented at the American Thoracic Society 2014 International Conference -- SAN DIEGO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a placebo-controlled, Phase 2a challenge study in healthy adult patients ... ...
59 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home